Valeant Pharmaceuticals (NYSE:VRX) hasn't missed a beat despite its failed takeover bid for Botox maker Allergan (NYSE:AGN). Valeant lost out Monday to a competing bid from generic drugmaker Actavis (NYSE:ACT), which said it would buy Allergan for $66 billion. Yet Valeant climbed 2% in heavy volume that day, clearing a 135.68 buy point from a handle on a long consolidation. It's now nearly 5% past the buy point, just in buying range. The base is third stage, which is riskier than those that form earlier in a stock's run. But Valeant's Accumulation/Distribution Rating is A-, indicating strong demand
